TRx and NRx for Belviq (ARNA) were up 10% and 9% last week respectively, outstripping Qsymia (VVUS) TRx and NRx growth of 7% and 6%.
Sentiment: Strong Buy
I believe that the 4th consecutive week B growth has out paced Q
Nice as many perdict we will be the number 1 choice.. and Bel-Fen makes VVUS go out of busniness (unless they have another drug coming)
the fact that both were up is a big plus. Current Q patients will become future Bel-phen patients when available, or maybe even off label, before it's approved.
Excellent, I got an email confirming those numbers.